Debate: Salvage Therapy For Multiple Myeloma - Should Be The Same For Everyone

Debate: Salvage therapy for multiple myeloma - Should be the same for everyone

Debate: The best multiple myeloma salvage therapy - Novel therapy

Debate: The best multiple myeloma salvage therapy - KRD

Four drug regimens should be standard for myeloma salvage therapy

Debate: Ideal Treatment fro Smoldering Myeloma

Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024

HealthTree Foundation for Multiple Myeloma

Debate: Is allotransplant relevant today in myeloma? - Yes

Debate: Optimal Induction Therapy for Newly Diagnosed Transplant Eligible Myeloma - Triplets

DEBATE: One size fits all? Should everyone eligible get upfront autologous SCT - Pro

Debate: What is the best induction therapy in transplant-eligible myeloma patients? - Sequential

Debate: Patients with Early Relapsed MM should Receive 3-Drug Salvage Therapy

Q&A: Autologous Transplant for Young Standard-Risk Myeloma Patients? - Blood Cancer OncTalk 2023

GRACE - Global Resource for Advancing Cancer Education

Debate: Should alkylators be used upfront in transplant-ineligible myeloma patients? - No

Multiple Myeloma Update: Maintenance Therapy

Debate: Induction therapy for multiple myeloma - Based on an IMiD and a proteasome inhibitor

Roundtable discussion—Multiple Myeloma Hub Satellite Symposium: Should 'cure' be the goal for MM?

Multiple Myeloma Hub

MCRT Detroit 2017: Jeffrey Zonder, MD on Combo Regimens, Transplants, and Clinical Trials

HealthTree Foundation for Multiple Myeloma

DEBATE: One size fits all? Should everyone eligible get upfront autologous SCT - Con

Should we delay transplantation in patients with standard-risk multiple myeloma?

VJHemOnc – Video Journal of Hematology & HemOnc

Debate: Myeloma maintenance post-transplant - None or Limited